NASDAQ:ITCI Intra-Cellular Therapies Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Intra-Cellular Therapies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $26.88 +0.68 (+2.60 %) (As of 09/25/2020 12:00 AM ET) Add Compare Share Today's Range$26.20Now: $26.88▼$27.4950-Day Range$17.61MA: $22.35▼$31.8652-Week Range$6.75Now: $26.88▼$43.56Volume1.32 million shsAverage Volume1.37 million shsMarket Capitalization$1.81 billionP/E RatioN/ADividend YieldN/ABeta1.68 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases. It is also developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for Parkinson's disease; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingIntra-Cellular Therapies has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $53.33, Intra-Cellular Therapies has a forecasted upside of 98.4% from its current price of $26.88.Amount of Analyst CoverageIntra-Cellular Therapies has only been the subject of 2 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesIntra-Cellular Therapies has received 438 “outperform” votes. (Add your “outperform” vote.)Underperform VotesIntra-Cellular Therapies has received 410 “underperform” votes. (Add your “underperform” vote.)Community SentimentIntra-Cellular Therapies has received 51.65% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Intra-Cellular Therapies and other stocks. Vote “Outperform” if you believe ITCI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ITCI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldIntra-Cellular Therapies does not currently pay a dividend.Dividend GrowthIntra-Cellular Therapies does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Intra-Cellular Therapies insiders have bought 57.18% more of their company's stock than they have sold. Specifically, they have bought $2,054,880.00 in company stock and sold $1,307,351.00 in company stock.Percentage Held by InsidersOnly 18.20% of the stock of Intra-Cellular Therapies is held by insiders.Percentage Held by Institutions71.91% of the stock of Intra-Cellular Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($3.66) to ($3.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intra-Cellular Therapies is -8.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intra-Cellular Therapies is -8.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntra-Cellular Therapies has a P/B Ratio of 7.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.13 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ITCI Previous Symbol CUSIPN/A CIK1567514 Webwww.intracellulartherapies.com Phone646-440-9333Debt Debt-to-Equity RatioN/A Current Ratio10.40 Quick Ratio10.34Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$60,000.00 Price / Sales30,153.09 Cash FlowN/A Price / Cash FlowN/A Book Value$3.52 per share Price / Book7.64Profitability EPS (Most Recent Fiscal Year)($2.68) Net Income$-147,720,000.00 Net MarginsN/A Return on Equity-60.58% Return on Assets-51.33%Miscellaneous Employees73 Outstanding Shares67,306,000Market Cap$1.81 billion Next Earnings Date11/3/2020 (Estimated) OptionableOptionable $26.88 +0.68 (+2.60 %) (As of 09/25/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ITCI News and Ratings via Email Sign-up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter. Intra-Cellular Therapies (NASDAQ:ITCI) Frequently Asked Questions How has Intra-Cellular Therapies' stock been impacted by Coronavirus (COVID-19)? Intra-Cellular Therapies' stock was trading at $17.77 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ITCI shares have increased by 51.3% and is now trading at $26.88. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Intra-Cellular Therapies? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Intra-Cellular Therapies. When is Intra-Cellular Therapies' next earnings date? Intra-Cellular Therapies is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020. View our earnings forecast for Intra-Cellular Therapies. How were Intra-Cellular Therapies' earnings last quarter? Intra-Cellular Therapies Inc (NASDAQ:ITCI) released its quarterly earnings data on Monday, August, 10th. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing the Zacks' consensus estimate of ($0.94) by $0.02. The biopharmaceutical company earned $1.91 million during the quarter, compared to the consensus estimate of $3.05 million. View Intra-Cellular Therapies' earnings history. What price target have analysts set for ITCI? 6 Wall Street analysts have issued 1 year price targets for Intra-Cellular Therapies' shares. Their forecasts range from $26.00 to $80.00. On average, they expect Intra-Cellular Therapies' stock price to reach $53.33 in the next year. This suggests a possible upside of 98.4% from the stock's current price. View analysts' price targets for Intra-Cellular Therapies. Are investors shorting Intra-Cellular Therapies? Intra-Cellular Therapies saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 6,740,000 shares, an increase of 26.2% from the August 31st total of 5,340,000 shares. Based on an average daily trading volume, of 1,800,000 shares, the short-interest ratio is currently 3.7 days. View Intra-Cellular Therapies' Short Interest. Who are some of Intra-Cellular Therapies' key competitors? Some companies that are related to Intra-Cellular Therapies include Myokardia (MYOK), Ionis Pharmaceuticals (IONS), ACADIA Pharmaceuticals (ACAD), Perrigo (PRGO), Bausch Health Companies (BHC), Emergent Biosolutions (EBS), Ultragenyx Pharmaceutical (RARE), Blueprint Medicines (BPMC), Zai Lab (ZLAB), Arrowhead Pharmaceuticals (ARWR), BridgeBio Pharma (BBIO), United Therapeutics (UTHR), HUTCHISON CHINA/S (HCM), Arena Pharmaceuticals (ARNA) and MorphoSys (MOR). View all competitors. What other stocks do shareholders of Intra-Cellular Therapies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Amarin (AMRN), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Crispr Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), AbbVie (ABBV), Clovis Oncology (CLVS) and Pfizer (PFE). Who are Intra-Cellular Therapies' key executives? Intra-Cellular Therapies' management team includes the following people: Dr. Sharon Mates, Co-Founder, Chairman, CEO & Pres (Age 66)Mr. Lawrence J. Hineline CPA, Sr. VP of Fin., CFO, Treasurer and Assistant Sec. (Age 63)Dr. Robert E. Davis, Sr. VP & Chief Scientific Officer (Age 68)Mr. Michael I. Halstead J.D., Exec. VP, Gen. Counsel, Corp. Compliance Officer & Sec. (Age 46)Dr. Andrew Satlin M.D., Exec. VP & Chief Medical Officer (Age 64) What is Intra-Cellular Therapies' stock symbol? Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI." Who are Intra-Cellular Therapies' major shareholders? Intra-Cellular Therapies' stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (12.67%), Vanguard Group Inc. (7.83%), Bellevue Group AG (5.62%), Wasatch Advisors Inc. (5.51%), Marshall Wace LLP (1.98%) and Nuveen Asset Management LLC (1.02%). Company insiders that own Intra-Cellular Therapies stock include Andrew Satlin, Christopher D Alafi, Joel S Marcus, Kimberly E Vanover, Lawrence J Hineline, Mark Neumann, Michael Halstead, Robert E Davis and Sharon Mates. View institutional ownership trends for Intra-Cellular Therapies. Which institutional investors are selling Intra-Cellular Therapies stock? ITCI stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Alyeska Investment Group L.P., Hudson Bay Capital Management LP, Rhenman & Partners Asset Management AB, Atom Investors LP, UBS Group AG, Bank of America Corp DE, and TD Asset Management Inc.. Company insiders that have sold Intra-Cellular Therapies company stock in the last year include Andrew Satlin, Joel S Marcus, Lawrence J Hineline, Mark Neumann, Michael Halstead, and Sharon Mates. View insider buying and selling activity for Intra-Cellular Therapies. Which institutional investors are buying Intra-Cellular Therapies stock? ITCI stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Wasatch Advisors Inc., Marshall Wace LLP, Pinnacle Associates Ltd., Bailard Inc., Goldman Sachs Group Inc., Assenagon Asset Management S.A., and Nuveen Asset Management LLC. View insider buying and selling activity for Intra-Cellular Therapies. How do I buy shares of Intra-Cellular Therapies? Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Intra-Cellular Therapies' stock price today? One share of ITCI stock can currently be purchased for approximately $26.88. How big of a company is Intra-Cellular Therapies? Intra-Cellular Therapies has a market capitalization of $1.81 billion and generates $60,000.00 in revenue each year. The biopharmaceutical company earns $-147,720,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Intra-Cellular Therapies employs 73 workers across the globe. What is Intra-Cellular Therapies' official website? The official website for Intra-Cellular Therapies is www.intracellulartherapies.com. How can I contact Intra-Cellular Therapies? Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 646-440-9333 or via email at [email protected] This page was last updated on 9/27/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
